ClinicalTrials.gg
RecruitingNCT07701486VIRAGE2Updated Oct 22, 2026

A Study of More Frequent Dosing of VCN-01 Combined With Standard Chemotherapy in Patients With Newly Diagnosed Metastatic Pancreatic Cancer

A Phase 1/2 interventional study of VCN-01 oncolytic adenovirus (zabilugene almadenorepvec) and Nab-paclitaxel + Gemcitabine in Pancreas Cancer, Metastatic, Pancreas Cancer, Stage IV and Ductal Adenocarcinoma of the Pancreas, sponsored by Theriva Biologics SL. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Theriva Biologics SL · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.
Updated Oct 22, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 202 studies in Pancreatic Neoplasms with a site in Spain — 46 open to participants now, 69 under way, 11 of them phase 3. Pancreatic Neoplasms · Spain.

Planned enrollment
173rd of 174
6 · median 146
Started
2026
with 12 others
Phase 1/2
34 of 202
10 open now
Primary completion
2027-08
later than 35 of 68 live
Registered
200th of 202
by date

Among the 202 studies in Pancreatic Neoplasms with a site in Spain, this one is the 173rd largest by planned enrollment of the 174 interventional ones that give a count, is one of 13 that started in 2026, is one of 34 in phase 1/2, reaches primary completion later than 35 of the 68 other live ones, and was the 200th registered.

Pancreatic Neoplasms

3,903 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

46 of the 202 studies in Pancreatic Neoplasms with a site in Spain are open now. Recruiting first, the newest first:

40 more — sign in →

All 46 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 153 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 202 studies in Pancreatic Neoplasms with a site in Spain, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if the new administration regimen of VCN-01, given together with the standard chemotherapy drugs gemcitabine and nab-paclitaxel (GnP), is safe and well tolerated. The behaviour of VCN-01 in the organism will be assessed, together with the possible benefits of this administration regimen. This study includes adults with newly diagnosed pancreatic ductal adenocarcinoma (PDAC) that has spread to other parts of the body (stage IV) and who have not received prior treatment for pancreatic cancer.

Participants will receive three planned doses of VCN-01, given once every 56 days. Each dose of VCN-01 is followed one week later by two cycles of standard chemotherapy with gemcitabine and nab-paclitaxel. Participants will be monitored throughout the study for safety and side effects.

03

Conditions studied

  • Pancreas Cancer, Metastatic
  • Pancreas Cancer, Stage IV
  • Ductal Adenocarcinoma of the Pancreas

Keywords

  • VCN-01
  • mPDAC
  • gemcitabine
  • nab-paclitaxel
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written obtained prior to initiating any trial-specific procedures or assessments.
  • Male or female patients aged 18 years or over.
  • Patients with or cytologically confirmed pancreatic adenocarcinoma that is (stage IV) at diagnosis and who have not received any treatment for their pancreatic cancer.
  • Patients must be able to receive their first dose of VCN-01 ≤6 weeks after their metastatic pancreatic cancer diagnosis.
  • Patients must have at least one measurable tumor lesion that can be imaged for assessments according to 1.1.
  • performance status of 0 or 1 at enrollment.
  • Must be willing to comply with the trial intervention, including prophylactic medications, and procedures.
  • Adequate baseline organ function (hematologic, liver, renal) within the 7 days prior to enrollment:

Hematology:

  • Leukocytes ≥3.0x103 mcL
  • ≥1.5x10⁹/L
  • ≥9 g/dL
  • ≥100x10⁹/L

Coagulation:

  • or international normalized ratio ≤1x (ULN)
  • Activated partial thromboplastin time ≤1.2xULN

Hepatic:

  • Total ≤1.5xULN
  • and AST ≤2.5xULN (\<5xULN is acceptable if liver metastases are present)

Renal:

  • Serum creatinine ≤1.5xULN; or,
  • If serum creatinine >1.5xULN, an estimated >50 mL/min using the Cockcroft and Gault formula

Nutritional:

  • Serum Albumin ≥30 g/L

- Adequate (LVEF) ≥ 50% measured by ECHO or MUGA and corrected by Fridericia (QTcF) assessment ≤ 450 ms for men or ≤ 470 ms for women.

Exclusion criteria

Exclusion Criteria:

  • Unwillingness to complete the trial procedures for geographic, psychiatric, or social reasons.
  • Patient has previously received treatment for their pancreatic cancer with surgery, radiotherapy, chemotherapy or therapy; except that:
  • Palliative radiotherapy for pain is permitted;
  • Placement of a biliary stent/tube is permitted.
  • Patients who, in the opinion of the investigator, have symptoms or signs suggesting clinically unacceptable deterioration during the Screening Period.
  • Active infection or other serious illness or disease at the moment of enrollment. Active infection includes:

    • Tuberculosis (TB; clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice.
  • Patients with past or resolved TB are eligible to participate.

    • Virus (HBV; positive HBV surface antigen [HBsAg] result).
  • HBV carriers (patients positive for HBsAg without an active infection) are not eligible to participate;
  • Patients requiring antiviral medicines for HBV prophylaxis or treatment are not eligible to participate;
  • Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [HBcAb] and absence of HBsAg) are eligible to participate provided that blood HBV DNA is negative at enrollment.

    • Virus (HCV; positive HCV Ribonucleic acid [RNA]).
  • Patients requiring antiviral medicines for HCV prophylaxis or treatment are not eligible to participate;
  • Patients positive for HCV antibody are eligible to participate (only if polymerase chain reaction is negative for HCV RNA).

    • (positive HIV 1/2 antibodies)

Active infection or other serious illness or autoimmune disease at the moment of enrollment. Active infection includes:

  • Tuberculosis (TB; clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice.

    - Patients with past or resolved TB are eligible to participate.

  • Hepatitis B Virus (HBV; positive HBV surface antigen [HBsAg] result).

    • HBV carriers (patients positive for HBsAg without an active infection) are not eligible to participate;
    • Patients requiring antiviral medicines for HBV prophylaxis or treatment are not eligible to participate;
    • Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [HBcAb] and absence of HBsAg) are eligible to participate provided that blood HBV DNA is negative at enrollment.
  • Hepatitis C Virus (HCV; positive HCV Ribonucleic acid [RNA]).

    • Patients requiring antiviral medicines for HCV prophylaxis or treatment are not eligible to participate;
    • Patients positive for HCV antibody are eligible to participate (only if polymerase chain reaction is negative for HCV RNA).
  • Human immunodeficiency virus (positive HIV 1/2 antibodies)

    • Known chronic liver disease (e.g. liver cirrhosis, liver fibrosis, chronic hepatitis); except that:
    • Patients with fatty liver disease are eligible to participate if their liver transaminases meet inclusion criterion 8.
    • Concurrent malignant hematologic or solid disease; except that:
    • Patients with a prior history of cancer are eligible to participate if they are in complete remission from their prior cancer for at least 3 years.
    • Patients with Li Fraumeni syndrome or with previously known retinoblastoma protein pathway germline deficiency.
    • Patients with untreated and/or with progressive symptoms despite coverage; except that:
    • Patients with brain metastases with stable symptoms are eligible to participate.
    • Patients with previous pneumonitis or interstitial lung disease.
    • Patients with pre-existing sensory neuropathy >G1
    • Clinical evidence of deep vein thrombosis, pulmonary embolism or arterial thromboembolic event during the Screening Period.
    • Patients with superficial vein thrombosis are eligible to participate.
    • Patients with uncontrolled coagulopathy.
    • Any other condition, disease, metabolic dysfunction (e.g., uncontrolled diabetes mellitus), active or uncontrolled infection/inflammation, physical examination finding, mental state or clinical laboratory finding that would contraindicate participation in the clinical trial due to concerns over safety or potential non-compliance with clinical trial procedures.
    • A female patient, who is pregnant or lactating.
    • Female patients of must agree to use a highly effective method of . Male patients must agree to use condoms.
    • Treatment with in the last 3 weeks before the administration of the IMP.
    • Treatment with an adenovirus type-5 (Ad5)-based COVID-vaccine in the last 12 weeks before the administration of the IMP.
    • Treatment with another investigational agent within five of that investigational agent's half-lives prior to the administration of the IMP.
    • Chronic therapy; except that:
    • Inhaled corticosteroids are permitted;
    • Oral or IV corticosteroids with a dose lower than 10 mg prednisone or equivalent/day are permitted;
    • Dexamethasone up to a maximum dose of 1 mg/day is permitted.
    • Known allergy or to any of the trial-specific interventions or any of their .
    • Subjects, for whom treatment options other than the combination nab-paclitaxel/gemcitabine are recommended by the investigator.
Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (estimated)

Study arms

  • Experimental
    High dose

    The initial dosing regimen for this study comprises three "macrocycles", each of which comprises one dose of VCN-01 followed one week later by 2 cycles of GnP according to standard of care

    Biological: VCN-01 oncolytic adenovirus (zabilugene almadenorepvec) · Drug: Nab-paclitaxel + Gemcitabine

Interventions

  • BiologicalVCN-01 oncolytic adenovirus (zabilugene almadenorepvec)

    The initial dosing regimen for this study comprises up to three "macrocycles", each of which comprises one dose of VCN-01 followed one week later by 2 cycles of GnP according to standard of care (SoC)

  • DrugNab-paclitaxel + Gemcitabine

    Drug pages: Albumin-Bound PaclitaxelStudies of Albumin-Bound PaclitaxelAlbumin-Bound Paclitaxel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · GemcitabineStudies of GemcitabineGemcitabine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    IV nab-paclitaxel (starting dose 125 mg/m²) followed by IV gemcitabine (starting dose 1,000 mg/m²) according to SoC clinical practice (GnP SoC). Dose modifications and interruptions permitted per prescribing information/SmPC.

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events

    Frequency and proportion of participants experiencing AEs/SAEs; descriptive statistics for laboratory values.

    Time frame: From enrolment up to 30-days from the last dose of study intervention

  2. Pharmacokinetics (PK) of VCN-01

    VCN-01 concentration in blood at predefined time points.

    Time frame: From enrollment up to 30 days from the last dose of study intervention

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Aug 2027, 12 months after the start.

Of 114 industry-sponsored phase 1/2 interventional studies under Pancreatic Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 88. This study's planned 12 months is below that.

Counting every sponsor, half of 209 studies reached it within 51 months; a quarter within 36 and three quarters within 89.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Jul 2026, on Oct 22, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2026
First posted
Jul 14, 2026
StartActual
Jul 31, 2026was Aug 2026
Primary completionEst.
Aug 1, 2027
CompletionEst.
Dec 1, 2027
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 3, 2026→Jul 31, 2026 (actual)
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Start date Aug 3, 2026→Jul 31, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07701486
Lead sponsor
Theriva Biologics SL
Responsible party
Sponsor
First posted
Jul 14, 2026
Start date
Jul 31, 2026
Primary completion
Aug 1, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Oct 22, 2026

Study contacts

Manel Cascalló CEO, PhD
Contact
mcascallo@therivabio.com
+93936899365

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion